At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 44 enrolled
Drug / intervention
Mild dose cannabis +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
CCRC: The Analgesic Effect of Vaporized Cannabis on Neuropathic Pain
In Brief
A Phase 2 clinical trial evaluating Mild dose cannabis, Low dose cannabis, and 1 other intervention for Neuropathic Pain and 5 related conditions. Completed, enrolled 44 participants across 1 site.
Detailed Summary
This study theorized that a low dose of vaporized cannabis could alleviate nerve injury pain.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuropathic Pain, Reflex Sympathetic Dystrophy, Peripheral Neuropathy, Post-herpetic Neuralgia, Spinal Cord Injury, Multiple Sclerosis
CountriesUnited States
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2009
First PostedDec 2009
Primary CompletionNov 2012
TodayJul 2026
First PostedDec 21, 2009
Enrollment StartDec 1, 2009
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 16.5 years ago
Interventions
Mild dose cannabisdrug
3.53% THC by weight
Low dose cannabisdrug
1.29% THC by weight
Cannabisdrug
0.00% THC by weight